These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1711719)

  • 21. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay.
    Kaplan AP; Gruber B; Harpel PC
    Blood; 1985 Sep; 66(3):636-41. PubMed ID: 3875374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor.
    Gluszko P; Undas A; Amenta S; Szczeklik A; Schmaier AH
    J Lab Clin Med; 1994 Feb; 123(2):232-40. PubMed ID: 8301199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombin-stimulated platelet aggregation is inhibited by kallikrein in a time- and concentration-dependent manner.
    Veloso D
    Scand J Clin Lab Invest; 2003; 63(4):279-86. PubMed ID: 12940636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma.
    Lewin MF; Kaplan AP; Harpel PC
    J Biol Chem; 1983 May; 258(10):6415-21. PubMed ID: 6343376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prekallikrein activation in the adult respiratory distress syndrome.
    Schapira M; Gardaz JP; Py P; Lew PD; Perrin LH; Suter PM
    Bull Eur Physiopathol Respir; 1985; 21(3):237-41. PubMed ID: 3873975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose dependence of endotoxin-induced activation of the plasma contact system: an in vitro study.
    Roeise O; Bouma BN; Stadaas JO; Aasen AO
    Circ Shock; 1988 Dec; 26(4):419-30. PubMed ID: 2463883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computerized immunoblot analyses (CIBA) of the distribution of prekallikrein and its activation products in vivo and in vitro.
    Veloso D; Campbell G
    Agents Actions Suppl; 1992; 38 ( Pt 1)():166-73. PubMed ID: 1281607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunochemical studies of plasma kallikrein.
    Bagdasarian A; Lahiri B; Talamo RC; Wong P; Colman RW
    J Clin Invest; 1974 Dec; 54(6):1444-54. PubMed ID: 4140197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure and function of C1 inhibitor.
    Davis AE
    Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis.
    Kaufman N; Page JD; Pixley RA; Schein R; Schmaier AH; Colman RW
    Blood; 1991 Jun; 77(12):2660-7. PubMed ID: 1710516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC).
    Lämmle B; Tran TH; Ritz R; Duckert F
    Am J Clin Pathol; 1984 Oct; 82(4):396-404. PubMed ID: 6206713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the role of the C1-esterase inhibitor in cold urticaria.
    Nilsson T; Bäck O
    Acta Derm Venereol; 1984; 64(3):197-202. PubMed ID: 6204479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.
    Schapira M; Scott CF; Colman RW
    J Clin Invest; 1982 Feb; 69(2):462-8. PubMed ID: 6173399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor.
    Joseph K; Tholanikunnel BG; Kaplan AP
    J Allergy Clin Immunol; 2009 Jul; 124(1):143-9. PubMed ID: 19342086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Level of plasma prekallikrein and its inhibitors in reactors and nonreactors during intravenous enhancement with contrast media.
    Aronen HJ; Kivisaari L; Torstila I; Paavonen T; Meri S; Karonen SL; Standertskjöld-Nordenstam CG
    Acta Radiol; 1992 Jul; 33(4):374-8. PubMed ID: 1378750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease of plasma prekallikrein and kallikrein inhibitors during intravenous phlebography.
    Aronen HJ; Torstila I; Vahtera E; Suoranta HT
    Eur J Radiol; 1988 Feb; 8(1):30-3. PubMed ID: 2451609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.
    Levi M; Roem D; Kamp AM; de Boer JP; Hack CE; ten Cate JW
    Thromb Haemost; 1993 Feb; 69(2):141-6. PubMed ID: 7681223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma.
    España F; Estelles A; Griffin JH; Aznar J
    Thromb Haemost; 1991 Jan; 65(1):46-51. PubMed ID: 1850876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The critical concentration of C1-esterase inhibitor (C1-INH) in human serum preventing auto-activation of the first component of complement (C1).
    Windfuhr JP; Alsenz J; Loos M
    Mol Immunol; 2005 Apr; 42(6):657-63. PubMed ID: 15781109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes.
    Harpel PC; Lewin MF; Kaplan AP
    J Biol Chem; 1985 Apr; 260(7):4257-63. PubMed ID: 2579948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.